| Risk of fetal death after pandemic influenza virus infection or vaccination SE Håberg, L Trogstad, N Gunnes, AJ Wilcox, HK Gjessing, ... New England Journal of Medicine 368 (4), 333-340, 2013 | 349 | 2013 |
| Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease J Holst, B Feiring, JE Fuglesang, EA Høiby, H Nøkleby, IS Aaberge, ... Vaccine 21 (7-8), 734-737, 2003 | 210 | 2003 |
| The concept of “tailor-made”, protein-based, outer membrane vesicle vaccines against meningococcal disease J Holst, B Feiring, LM Næss, G Norheim, P Kristiansen, EA Høiby, K Bryn, ... Vaccine 23 (17-18), 2202-2205, 2005 | 125 | 2005 |
| Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: a brief survey. EA Høiby, E Rosenqvist, LO Frøholm, G Bjune, B Feiring, H Nøkleby, ... NIPH annals 14 (2), 147-55; discussion 155, 1991 | 101 | 1991 |
| Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease H Nøkleby, P Aavitsland, J O’hallahan, B Feiring, S Tilman, P Oster Vaccine 25 (16), 3080-3084, 2007 | 95 | 2007 |
| Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control V Thornton, D Lennon, K Rasanathan, J O’hallahan, P Oster, J Stewart, ... Vaccine 24 (9), 1395-1400, 2006 | 87 | 2006 |
| The Norwegian immunisation register–SYSVAK L Trogstad, G Ung, M Hagerup-Jenssen, I Cappelen, IL Haugen, B Feiring Eurosurveillance 17 (16), 20147, 2012 | 85 | 2012 |
| HPV vaccination and risk of chronic fatigue syndrome/myalgic encephalomyelitis: a nationwide register-based study from Norway B Feiring, I Laake, IJ Bakken, M Greve-Isdahl, VB Wyller, SE Håberg, ... Vaccine 35 (33), 4203-4212, 2017 | 70 | 2017 |
| Do parental education and income matter? A nationwide register-based study on HPV vaccine uptake in the school-based immunisation programme in Norway B Feiring, I Laake, T Molden, I Cappelen, SE Håberg, P Magnus, ... BMJ open 5 (5), e006422, 2015 | 70 | 2015 |
| Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines S Sandbu, B Feiring, P Oster, OS Helland, HSW Bakke, LM Næss, A Aase, ... Clinical and Vaccine Immunology 14 (9), 1062-1069, 2007 | 64 | 2007 |
| Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine B Feiring, J Fuglesang, P Oster, LM Næss, OS Helland, S Tilman, ... Clinical and Vaccine Immunology 13 (7), 790-796, 2006 | 62 | 2006 |
| Substantial decline in prevalence of vaccine-type and nonvaccine-type human papillomavirus (HPV) in vaccinated and unvaccinated girls 5 years after implementing HPV vaccine in … B Feiring, I Laake, IK Christiansen, M Hansen, J Stålcrantz, OH Ambur, ... The Journal of infectious diseases 218 (12), 1900-1910, 2018 | 57 | 2018 |
| Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks. MK Taha, ML Zarantonelli, JM Alonso, LM Næss, J Holst, B Feiring, ... | 40 | 2007 |
| Human antibody responses after vaccination with the Norwegian group B meningococcal outer membrane vesicle vaccine: results from ELISA studies. E Rosenqvist, EA Høiby, G Bjune, K Bryn, O Closs, B Feiring, A Klem, ... NIPH annals 14 (2), 169-79; discussion 180, 1991 | 29 | 1991 |
| Impact and cost-effectiveness of strategies to accelerate cervical cancer elimination: A model-based analysis A Portnoy, K Pedersen, L Trogstad, BT Hansen, B Feiring, I Laake, ... Preventive medicine 144, 106276, 2021 | 25 | 2021 |
| Human papillomavirus prevalence and type distribution in urine samples from Norwegian women aged 17 and 21 years: A nationwide cross-sectional study of three non-vaccinated … T Molden, B Feiring, OH Ambur, IK Christiansen, M Hansen, I Laake, ... Papillomavirus Research 2, 153-158, 2016 | 20 | 2016 |
| The Norwegian meningococcal group B outer membrane vesicle vaccine: side effects in phase II trials. H Nøkleby, B Feiring NIPH annals 14 (2), 95-101; discussion 101, 1991 | 20 | 1991 |
| Do selective immunisation against tuberculosis and hepatitis B reach the targeted populations? A nationwide register-based study evaluating the recommendations in the Norwegian … B Feiring, I Laake, T Molden, SE Håberg, H Nøkleby, SS Seterelv, ... Vaccine 34 (17), 2015-2020, 2016 | 19 | 2016 |
| Usefulness of health registries when estimating vaccine effectiveness during the influenza A (H1N1) pdm09 pandemic in Norway BR Guzmán Herrador, P Aavitsland, B Feiring, MA Riise Bergsaker, ... BMC infectious diseases 12, 1-6, 2012 | 19 | 2012 |
| Combined administration of meningococcal serogroup B outer membrane vesicle vaccine and conjugated serogroup C vaccine indicated for prevention of meningococcal disease is safe … IS Aaberge, P Oster, OS Helland, AC Kristoffersen, E Ypma, EA Høiby, ... Clinical and Vaccine Immunology 12 (5), 599-605, 2005 | 19 | 2005 |
